Imugene Limited (ASX:IMUOE)

Australia flag Australia · Delayed Price · Currency is AUD · Warrants
0.0010
0.00 (0.00%)
At close: Apr 16, 2026
Market Cap103.54M -73.2%
Revenue (ttm)4.40M -11.5%
Net Income-69.02M
EPS-0.32
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume105,883
Average Volume26,901
Open0.0010
Previous Closen/a
Day's Range0.0010 - 0.0010
52-Week Range0.0010 - 0.3060
Betan/a
RSI32.11
Earnings DateNov 27, 2025

About Imugene

Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tum... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Leslie Chong
Employees 15
Stock Exchange Australian Securities Exchange
Ticker Symbol IMUOE